{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:37:46Z","timestamp":1740166666197,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The emergence of HIV drug resistance presents a substantial challenge. Current antiretroviral treatments, along with current classes, face the danger of becoming partially or entirely inactive. As a result, alternative treatment regimens are limited, and treatment choices are complicated. According to the recommendation of the WHO, nations should consider changing their first-line ART regimen if HIV drug resistance exceeds 10%. In spite of the fact that a number of primary studies have been performed on HIV drug resistance in Ethiopia, their pooled prevalence rate has not been determined in a systematic review and meta-analysis, which may provide stronger evidence. Therefore, the objective of this systematic review and meta-analysis will be to estimate the pooled prevalence rate of HIV1 drug resistance in patients with first-line treatment failure in Ethiopia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Primary studies will be identified from PubMed\/MEDLINE, Scopus, Embase, Web of Science Core Collection, and Google Scholar. The period of search will be from 01 April to 30 June 2024. Studies identified through the search strategies will first be screened by titles and abstracts. Included studies meeting established criteria will be evaluated for risk of bias using the JBI checklist. Data will be extracted, and the pooled prevalence rate of HIV drug resistance will be computed using STATA 14 software. Random effect models will be used when heterogeneity is suspected. The <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistic and its corresponding <jats:italic>P<\/jats:italic> value will be checked to distinguish heterogeneity. Additionally, publication bias and heterogeneity will be checked using visual funnel plots, Egger\u2019s test, trim-and-fill tests, meta-regression, and subgroup analysis. To present and synthesize the results, narrative synthesis will be performed to describe study characteristics and findings, and forest plots will be used to visually represent effect sizes and confidence intervals from individual studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Estimating the pooled prevalence rate of HIV drug resistance through a systematic review and meta-analysis improves the reliability of the evidence, the availability of effective HIV treatment options, and the ability to assist in making decisions for both clinical practice and public health policy in Ethiopia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Systematic review registration<\/jats:title>\n                <jats:p>PROSPERO CRD42024533975.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-024-02605-1","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:09:57Z","timestamp":1721030997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIV1 drug resistance among patients experiencing first-line treatment failure in Ethiopia: protocol for a systematic review and meta-analysis"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5066-0758","authenticated-orcid":false,"given":"Melashu","family":"Balew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gedefaw","family":"Abeje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alemtsehay","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Getu","family":"Degu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"unstructured":"World Health Organization. Fact sheet HIV drug resistance, 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance.","key":"2605_CR1"},{"unstructured":"World Health Organization. HIV drug resistance report; 2021. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240038608.","key":"2605_CR2"},{"unstructured":"WorldHealthOrganization. HIV drug resistance, https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance#:~:text=HIV%20drug%20resistance%20is%20caused,of%20drug%2Dresistant%20virus%20strains.","key":"2605_CR3"},{"doi-asserted-by":"crossref","unstructured":"Chia HX, Tan SY, Ko KC, Tan RKJ, Lim J. HIV drug resistance in Southeast Asia: prevalence, determinants, and strategic management. J Public Health Emerg. 2022;6:1\u201326.","key":"2605_CR4","DOI":"10.21037\/jphe-22-5"},{"unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd ed; 2016. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789241549684.","key":"2605_CR5"},{"issue":"1","key":"2605_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12981-023-00572-6","volume":"20","author":"S SeyedAlinaghi","year":"2023","unstructured":"SeyedAlinaghi S, Afsahi AM, Moradi A, Parmoon Z, Habibi P, Mirzapour P, et al. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review. AIDS Res Ther. 2023;20(1):74.","journal-title":"AIDS Res Ther"},{"unstructured":"WHO. HIV drug resistance 2022 Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance.","key":"2605_CR7"},{"issue":"19","key":"2605_CR8","doi-asserted-by":"publisher","first-page":"e25763","DOI":"10.1097\/MD.0000000000025763","volume":"100","author":"M Nanfuka","year":"2021","unstructured":"Nanfuka M, Forrest JI, Zhang W, Okoboi S, Birungi J, Kaleebu P, et al. Durability of non-nucleotide reverse transcriptase inhibitor-based first-line ART regimens after 7 years of treatment in rural Uganda: a prospective cohort study. Medicine. 2021;100(19):e25763.","journal-title":"Medicine"},{"key":"2605_CR9","doi-asserted-by":"publisher","first-page":"1133407","DOI":"10.3389\/fmicb.2023.1133407","volume":"14","author":"A Temereanca","year":"2023","unstructured":"Temereanca A, Ruta S. Strategies to overcome HIV drug resistance-current and future perspectives. Front Microbiol. 2023;14:1133407.","journal-title":"Front Microbiol"},{"unstructured":"World Health Organization. Global action plan on HIV drug resistance; 2021. Available at: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance\/global-action-plan-and-strategy-on-hiv-drug-resistance.","key":"2605_CR10"},{"issue":"03","key":"2605_CR11","first-page":"65","volume":"9","author":"R-H Kang","year":"2020","unstructured":"Kang R-H, Liang S-J, Ma Y-L, Liang S, Xiao L, Zhang X-H, et al. Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017. Infect Dis Poverty. 2020;9(03):65\u201373.","journal-title":"Infect Dis Poverty"},{"unstructured":"Hamers RL. Drug-resistant HIV-1 in sub-Saharan Africa - research explorer. https:\/\/pure.uva.nl\/ws\/files\/2266065\/117277_thesis.pdf.","key":"2605_CR12"},{"issue":"37","key":"2605_CR13","doi-asserted-by":"publisher","first-page":"e21661","DOI":"10.1097\/MD.0000000000021661","volume":"99","author":"MR Jordan","year":"2020","unstructured":"Jordan MR, Hamunime N, Bikinesi L, Sawadogo S, Agolory S, Shiningavamwe AN, et al. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine. 2020;99(37):e21661.","journal-title":"Medicine"},{"key":"2605_CR14","doi-asserted-by":"publisher","first-page":"115628","DOI":"10.1016\/j.socscimed.2022.115628","volume":"317","author":"B Taverne","year":"2023","unstructured":"Taverne B, Laborde-Balen G, Sow K, Ndiaye NB, Diop K. Treatment success or failure in children and adolescents born with HIV in rural Senegal: an anthropological perspective. Soc Sci Med. 2023;317:115628.","journal-title":"Soc Sci Med"},{"key":"2605_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/HIV.S112048","volume":"8","author":"MB Ayalew","year":"2016","unstructured":"Ayalew MB, Kumilachew D, Belay A, Getu S, Teju D, Endale D, et al. First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar. Northwest Ethiopia HIV\/AIDS-Research and Palliative Care. 2016;8:141\u20136.","journal-title":"Northwest Ethiopia. HIV\/AIDS-Research and Palliative Care."},{"issue":"Suppl 1","key":"2605_CR16","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.4081\/idr.2013.s1.e5","volume":"5","author":"PS Pennings","year":"2013","unstructured":"Pennings PS. HIV drug resistance: problems and perspectives. Infectious disease reports. 2013;5(Suppl 1):e5.","journal-title":"Infectious disease reports."},{"key":"2605_CR17","volume-title":"HIV statistics, globally and by WHO region","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. HIV statistics, globally and by WHO region. 2023. https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/j0294-who-hiv-epi-factsheet-v7.pdf."},{"issue":"10","key":"2605_CR18","doi-asserted-by":"publisher","first-page":"e0276730","DOI":"10.1371\/journal.pone.0276730","volume":"17","author":"CI Penda","year":"2022","unstructured":"Penda CI, Moukoko Mbonjo M, Fokam J, Djeuda ABD, Grace N, Ateba Ndongo F, et al. Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon. PLoS ONE. 2022;17(10):e0276730.","journal-title":"PLoS ONE"},{"key":"2605_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-6405-11-9","volume":"11","author":"AS Hassan","year":"2014","unstructured":"Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, Rinke de Wit TF, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS research and therapy. 2014;11:1\u201312.","journal-title":"AIDS research and therapy."},{"issue":"8","key":"2605_CR20","doi-asserted-by":"publisher","first-page":"e0236156","DOI":"10.1371\/journal.pone.0236156","volume":"15","author":"S Miti","year":"2020","unstructured":"Miti S, Handema R, Mulenga L, Mwansa JK, Abrams E, Frimpong C, et al. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia. PLoS ONE. 2020;15(8):e0236156.","journal-title":"PLoS ONE"},{"unstructured":"MOH-E Fa. HIV\/AIDS National Strategic Plan (NSP) for Ethiopia 2021\u20132025. Available at: https:\/\/www.prepwatch.org\/wp-content\/uploads\/2022\/07\/Ethiopia-HIVAIDS-National-Strategic-Plan-2021-25.pdf.","key":"2605_CR21"},{"unstructured":"UNAIDS. Country factsheets, Ethiopia. 2023. Available at: https:\/\/www.unaids.org\/en\/regionscountries\/countries\/ethiopia.\u00a0","key":"2605_CR22"},{"unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. Guideline for hIV car\/ART clinical mentoring in Ethiopia; 2018. Available at: https:\/\/www.afro.who.int\/publications\/guideline-hiv-careart-clinical-mentoring-ethiopia.","key":"2605_CR23"},{"issue":"2","key":"2605_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/135965350801302S01","volume":"13","author":"WE Abegaz","year":"2008","unstructured":"Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, Sibide K, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa. Ethiopia Antiviral therapy. 2008;13(2):89\u201394.","journal-title":"Ethiopia. Antiviral therapy."},{"key":"2605_CR25","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.2147\/IDR.S337485","volume":"14","author":"E Tachbele","year":"2021","unstructured":"Tachbele E, Kyobe S, Katabazi FA, Kigozi E, Mwesigwa S, Joloba M, et al. Genetic diversity and acquired drug resistance mutations detected by deep sequencing in virologic failures among antiretroviral treatment experienced human immunodeficiency virus-1 patients in a pastoralist region of Ethiopia. Infection and Drug Resistance. 2021;14:4833\u201347.","journal-title":"Infection and Drug Resistance."},{"doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. 1st ed. Chichester (UK): Wiley; 2019. https:\/\/doi.org\/10.1002\/9781119536604.","key":"2605_CR26","DOI":"10.1002\/9781119536604"},{"key":"2605_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1\u20139.","journal-title":"Syst Rev"},{"unstructured":"Aromataris E, Munn Z. JBI manual for evidence synthesis. JBI, 2020 Available from: https:\/\/synthesismanual.jbi.global; https:\/\/doi.org\/10.46658.JBIMES-20\u201301.","key":"2605_CR28"},{"issue":"2","key":"2605_CR29","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1002\/cl2.1229","volume":"18","author":"K Saif-Ur-Rahman","year":"2022","unstructured":"Saif-Ur-Rahman K, Hasan M, Hossain S, Anwar I, Hirakawa Y, Yatsuya H. Prioritization and sequential exclusion of articles in systematic reviews. Campbell Syst Rev. 2022;18(2):e1229.","journal-title":"Campbell Syst Rev"},{"issue":"1","key":"2605_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/bph.16100","volume":"181","author":"K Kolaski","year":"2024","unstructured":"Kolaski K, Logan LR, Ioannidis JP. Guidance to best tools and practices for systematic reviews. Br J Pharmacol. 2024;181(1):180\u2013210.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2605_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","volume":"20","author":"W Melsen","year":"2014","unstructured":"Melsen W, Bootsma M, Rovers M, Bonten M. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20(2):123\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2605_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/bjsports-2021-103987","volume":"56","author":"CL Ardern","year":"2022","unstructured":"Ardern CL, B\u00fcttner F, Andrade R, Weir A, Ashe MC, Holden S, et al. Implementing the 27 PRISMA 2020 statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the PERSiST (implementing Prisma in Exercise, Rehabilitation, Sport medicine and SporTs science) guidance. Br J Sports Med. 2022;56(4):175\u201395.","journal-title":"Br J Sports Med"},{"issue":"5","key":"2605_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bja.2019.08.015","volume":"123","author":"A Granholm","year":"2019","unstructured":"Granholm A, Alhazzani W, M\u00f8ller MH. Use of the GRADE approach in systematic reviews and guidelines. Br J Anaesth. 2019;123(5):554\u20139.","journal-title":"Br J Anaesth"},{"key":"2605_CR34","doi-asserted-by":"publisher","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","volume":"25","author":"M Prasad","year":"2024","unstructured":"Prasad M. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clinical Epidemiology and Global Health. 2024;25:101484.","journal-title":"Clinical Epidemiology and Global Health"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-024-02605-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02605-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:19:11Z","timestamp":1721031551000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-024-02605-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2605"],"URL":"https:\/\/doi.org\/10.1186\/s13643-024-02605-1","relation":{},"ISSN":["2046-4053"],"issn-type":[{"type":"electronic","value":"2046-4053"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}